Articles

Sort by
Previous Page Page 2 of 58 Next Page
  1. Research article

    Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...

    James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm

    Journal for ImmunoTherapy of Cancer 2017 5:25

    Published on: 21 March 2017

  2. Research article

    Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

    Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...

    Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman and Xiuli Wang

    Journal for ImmunoTherapy of Cancer 2017 5:26

    Published on: 21 March 2017

  3. Research article

    Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

    T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...

    Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

    Journal for ImmunoTherapy of Cancer 2017 5:22

    Published on: 21 March 2017

  4. Meeting report

    Immunotherapy biomarkers 2016: overcoming the barriers

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...

    James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…

    Journal for ImmunoTherapy of Cancer 2017 5:29

    Published on: 21 March 2017

  5. Review

    Systematic evaluation of immune regulation and modulation

    Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...

    David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger

    Journal for ImmunoTherapy of Cancer 2017 5:21

    Published on: 21 March 2017

  6. Meeting abstracts

    Abstracts from the 4th ImmunoTherapy of Cancer Conference

    J. Ženka, V. Caisová, O. Uher, P. Nedbalová, K. Kvardová, K. Masáková, G. Krejčová, L. Paďouková, I. Jochmanová, K. I. Wolf, J. Chmelař, J. Kopecký, L. Loumagne, J. Mestadier, S. D’agostino, A. Rohaut…

    Journal for ImmunoTherapy of Cancer 2017 5(Suppl 1):12

    Published on: 20 March 2017

    This article is part of a Supplement: Volume 5 Supplement 1

  7. Case report

    Immunotherapy-associated autoimmune hemolytic anemia

    Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. Cytotoxic T-lymphocyte-...

    Uqba Khan, Farman Ali, Muhammad Siddique Khurram, Awais Zaka and Tarik Hadid

    Journal for ImmunoTherapy of Cancer 2017 5:15

    Published on: 21 February 2017

  8. Case report

    Nivolumab induced myxedema crisis

    Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed...

    Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu and Tarik Hadid

    Journal for ImmunoTherapy of Cancer 2017 5:13

    Published on: 21 February 2017

  9. Commentary

    FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

    Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Ji...

    Stefan N. Symeonides, Stephen M. Anderton and Alan Serrels

    Journal for ImmunoTherapy of Cancer 2017 5:17

    Published on: 21 February 2017

  10. Case report

    PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation

    Allogeneic hematopoietic stem cell transplantation and checkpoint blockade therapy are immune-based therapies that have activity in selected refractory hematologic malignancies. Interest has developed in combi...

    James Godfrey, Michael R. Bishop, Sahr Syed, Elizabeth Hyjek and Justin Kline

    Journal for ImmunoTherapy of Cancer 2017 5:11

    Published on: 21 February 2017

  11. Commentary

    Immunotherapy resistance: the answers lie ahead – not in front – of us

    Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manu...

    Miles C. Andrews and Jennifer A. Wargo

    Journal for ImmunoTherapy of Cancer 2017 5:10

    Published on: 21 February 2017

  12. Case report

    Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

    Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-...

    Eileen Shiuan, Kathryn E. Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P. Greer, Suthee Rapisuwon, Michael Postow, Michael A. Davies, Zeynep Eroglu and Douglas Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:8

    Published on: 21 February 2017

  13. Research article

    Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...

    Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom

    Journal for ImmunoTherapy of Cancer 2017 5:20

    Published on: 21 February 2017

  14. Research article

    Gene expression markers of Tumor Infiltrating Leukocytes

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...

    Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling

    Journal for ImmunoTherapy of Cancer 2017 5:18

    Published on: 21 February 2017

  15. Review

    Combination immunotherapy: a road map

    Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent yea...

    Patrick A. Ott, F. Stephen Hodi, Howard L. Kaufman, Jon M. Wigginton and Jedd D. Wolchok

    Journal for ImmunoTherapy of Cancer 2017 5:16

    Published on: 21 February 2017

  16. Research article

    Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...

    Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita

    Journal for ImmunoTherapy of Cancer 2017 5:9

    Published on: 21 February 2017

  17. Research article

    CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo

    Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...

    Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins and David Edward Gilham

    Journal for ImmunoTherapy of Cancer 2017 5:14

    Published on: 21 February 2017

  18. Erratum

    Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

    Marc Uemura, Faisal Fa’ak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff and Adi Diab

    Journal for ImmunoTherapy of Cancer 2017 5:7

    Published on: 18 January 2017

    The original article was published in Journal for ImmunoTherapy of Cancer 2016 4:55

  19. Case report

    Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma

    Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...

    Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell and Douglas B. Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:1

    Published on: 17 January 2017

  20. Commentary

    It’s a long way to the top (if you want to personalize immunotherapy)

    Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Fol...

    Sarah Haebe and Oliver Weigert

    Journal for ImmunoTherapy of Cancer 2017 5:6

    Published on: 17 January 2017

  21. Case report

    Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

    Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by thes...

    Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka and Jose Lutzky

    Journal for ImmunoTherapy of Cancer 2017 5:3

    Published on: 17 January 2017

Previous Page Page 2 of 58 Next Page
JITC logo

Advertisement